From CNBC:

Novo Nordisk CEO Lars Fruergaard Jørgensen announced that amycretin, a new weight loss pill, could be a leading treatment for obesity. Patients lost 13.1% of their weight after taking the pill for 12 weeks, surpassing Wegovy’s 6% weight loss. The pill targets gut hormone GLP-1 and pancreas hormone amylin for appetite suppression. Novo Nordisk aims to launch amycretin by the end of this decade. Shares of Novo Nordisk surged 8.3% after the announcement but fell 2% the following day.



Read more at CNBC: Weight loss pill could become a best-in-class drug